Preliminary Data on COVID-19 in Patients with Hemoglobinopathies: A Multicentre ICET-A Study.

COVID-19 Clinical course Patients’ characteristics Risk factors SARS-CoV-2 Sickle cell disease β-thalassemia

Journal

Mediterranean journal of hematology and infectious diseases
ISSN: 2035-3006
Titre abrégé: Mediterr J Hematol Infect Dis
Pays: Italy
ID NLM: 101530512

Informations de publication

Date de publication:
2020
Historique:
received: 30 05 2020
accepted: 14 06 2020
entrez: 17 7 2020
pubmed: 17 7 2020
medline: 17 7 2020
Statut: epublish

Résumé

This study aims to investigate, retrospectively, the epidemiological and clinical characteristics, laboratory results, radiologic findings, and outcomes of COVID-19 in patients with transfusion-dependent β thalassemia major (TM), β-thalassemia intermedia (TI) and sickle cell disease (SCD). A total of 17 Centers, from 10 countries, following 9,499 patients with hemoglobinopathies, participated in the survey. Clinical, laboratory, and radiologic findings and outcomes of patients with COVID-19 were collected from medical records and summarized. A total of 13 patients, 7 with TM, 3 with TI, and 3 with SCD, with confirmed COVID-19, were identified in 6 Centers from different countries. The overall mean age of patients was 33.7±12.3 years (range:13-66); 9/13 (69.2%) patients were females. Six patients had pneumonia, and 4 needed oxygen therapy. Increased C-reactive protein (6/10), high serum lactate dehydrogenase (LDH; 6/10), and erythrocyte sedimentation rate (ESR; 6/10) were the most common laboratory findings. 6/10 patients had an exacerbation of anemia (2 with SCD). In the majority of patients, the course of COVID-19 was moderate (6/10) and severe in 3/10 patients. A 30-year-old female with TM, developed a critical SARS-CoV-2 infection, followed by death in an Intensive Care Unit. In one Center (Oman), the majority of suspected cases were observed in patients with SCD between the age of 21 and 40 years. A rapid clinical improvement of tachypnea/dyspnea and oxygen saturation was observed, after red blood cell exchange transfusion, in a young girl with SCD and worsening of anemia (Hb level from 9.2 g/dl to 6.1g/dl). The data presented in this survey permit an early assessment of the clinical characteristics of COVID 19 in different countries. 70% of symptomatic patients with COVID- 19 required hospitalization. The presence of associated co-morbidities can aggravate the severity of COVID- 19, leading to a poorer prognosis irrespective of age.

Identifiants

pubmed: 32670524
doi: 10.4084/MJHID.2020.046
pii: mjhid-12-1-e2020046
pmc: PMC7340245
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e2020046

Déclaration de conflit d'intérêts

Competing interests: The authors declare no conflict of Interest.

Références

Mediterr J Hematol Infect Dis. 2015 Oct 13;7(1):e2015057
pubmed: 26543526
Pediatr Hematol Oncol. 2014 Oct;31(7):583-96
pubmed: 25247665
Clin Rev Allergy Immunol. 2019 Jun;56(3):308-321
pubmed: 28963611
Eur J Pediatr. 1982 Oct;139(2):135-8
pubmed: 7151834
Br J Haematol. 2020 Jul;190(2):e57-e58
pubmed: 32369606
Am J Hematol. 2020 Aug;95(8):E208-E210
pubmed: 32394480
Br J Haematol. 2020 Jul;190(1):e21-e24
pubmed: 32420608
Am J Hematol. 2020 Jun;95(6):725-726
pubmed: 32267016
Am J Hematol. 2020 Aug;95(8):E198-E199
pubmed: 32311145
Br J Haematol. 2020 Jun;189(5):851-852
pubmed: 32314798
Exp Biol Med (Maywood). 2016 Apr;241(7):679-88
pubmed: 27013545
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
Euro Surveill. 2020 Mar;25(10):
pubmed: 32183930
Am J Hematol. 2020 Aug;95(8):E192-E194
pubmed: 32358817
Epidemiol Health. 2020;42:e2020007
pubmed: 32035431
Acta Biomed. 2020 May 11;91(2):50-56
pubmed: 32420925
J Clin Med. 2020 Mar 30;9(4):
pubmed: 32235486
Ann Intern Med. 2020 May 6;:
pubmed: 32374815
Lancet Digit Health. 2020 Apr;2(4):e201-e208
pubmed: 32309796
Arch Acad Emerg Med. 2020 Mar 24;8(1):e35
pubmed: 32232218
Nat Rev Immunol. 2016 Oct;16(10):626-38
pubmed: 27546235
JAMA. 2020 Feb 24;:
pubmed: 32091533
Acta Biomed. 2020 May 11;91(2):216-217
pubmed: 32420949
Br J Haematol. 2020 Jun 2;:
pubmed: 32484906

Auteurs

Vincenzo de Sanctis (V)

Pediatric and Adolescent Outpatient Clinic, Quisisana Hospital, Ferrara, Italy.

Duran Canatan (D)

Antalya Genetic Diseases Diagnostic Center, Antalya, Turkey.

Joan Lluis Vives Corrons (JLV)

Red Blood Cell, and Haematopoietic Disorders Unit, Institute for Leukaemia Research Josep Carreras (IJC) and University of Barcelona, Catalonia, Spain. ENERCA Coordinator.

Mehran Karimi (M)

Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Shahina Daar (S)

Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos University, Sultanate of Oman.

Christos Kattamis (C)

First Department of Paediatrics, National Kapodistrian University of Athens, Athens, Greece.

Ashraf T Soliman (AT)

Pediatrics and Endocrinology Department of Pediatrics, Hamad Medical Center, Doha, Qatar and Department of Pediatrics, University of Alexandria, Alexandria, Egypt (Steering Committee).

Yasser Wali (Y)

Paediatric Hematology Unit, Child Health Department, College of Medicine, Sultan Qaboos University Oman and Department of Paediatrics, Faculty of Medicine, Alexandria University, Egypt.

Salam Alkindi (S)

Department of Haematology, College of Medicine and Health Sciences, Sultan Qaboos University, Sultanate of Oman.

Valeh Huseynov (V)

Center of Thalassemia, Baku, Azerbaijan.

Afag Nasibova (A)

Center of Thalassemia, Baku, Azerbaijan.

Tarık Onur Tiryaki (TO)

İstanbul University, Faculty of Medicine, Department of Hematology, İstanbul, Turkey.

Melike Sezgin Evim (MS)

Uludag University, Medical Faculty, Dept. of Pediatric Hematology, Bursa, Turkey.

Adalet Meral Gunes (AM)

Uludag University, Medical Faculty, Dept. of Pediatric Hematology, Bursa, Turkey.

Zeynep Karakas (Z)

Istanbul University, Istanbul Faculty of Medicine, Pediatric Hematology / Oncology, Istanbul, Turkey.

Soteroula Christou (S)

Archibishop Makarios III Hospital, Thalassaemia Clinic, Nicosia, Cyprus.

Saveria Campisi (S)

UOSD Thalassemia, Umberto I° Hospital, Siracusa, Italy.

Tahereh Zarei (T)

Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

Doaa Khater (D)

Department of Pediatric Endocrinology Alexandria University, Egypt and Department of Pediatrics, Sultan Qaboos University, Oman, Qatar.

Yesim Oymak (Y)

Dr. Behcet Uz Children's Hospital, Izmir, Turkey.

Valeriya Kaleva (V)

Expert Center for Coagulopathies and Rare Anemias, Varna, Bulgaria.

Denka Stoyanova (D)

Pediatric Hematoncology, University Hospital "Tzaritza Giovanna - ISUL," Sofia, Bulgaria.

Atanas Banchev (A)

Pediatric Hematoncology, University Hospital "Tzaritza Giovanna - ISUL," Sofia, Bulgaria.

Maria Concetta Galati (MC)

Pediatric Haematoncology, Pugliese-Ciaccio Hospital, Catanzaro, Italy.

Mohamed A Yassin (MA)

Hematology Section, National Center for Cancer Care and Research, Hamad Medical Corporation, (HMC), Doha, Qatar.

Shruti Kakar (S)

Pediatric Hematology Oncology, Department of Pediatrics, Dayanand Medical College and Hospital, Ludhiana, India.

Myrto Skafida (M)

First Department of Paediatrics, National Kapodistrian University of Athens, Athens, Greece.

Yurdanur Kilinc (Y)

Pediatric Hematology Department, Çukurova University, Adana, Turkey.

Saif Alyaarubi (S)

Pediatric Endocrinology Unit, Child Health Department, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman.

Narmin Verdiyevas (N)

Center of Thalassemia, Baku, Azerbaijan.

Iva Stoeva (I)

Paediatric Endocrinologist, Head "Screening and Functional Endocrine Diagnostics" University Paediatric Hospital, Sofia, Bulgaria.

Giuseppe Raiola (G)

Department of Paediatrics, Pugliese-Ciaccio Hospital, Catanzaro, Italy.

Demetris Mariannis (D)

Royal Lancaster Infirmary, Lancaster, UK.

Leopoldo Ruggiero (L)

Pediatrician, Lecce, Italy.

Salvatore Di Maio (S)

Emeritus Director in Pediatrics, "Santobono-Pausilipon" Children's Hospital, Naples, Italy.

Classifications MeSH